NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing studies assessing psychedelic-assisted therapy to treat nicotine addiction is showing efficacy rates two to three times higher than the current gold standard of treatment,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly. “Our team is eager to start collecting the data needed to bring an approved drug product to market that could potentially save millions of lives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing studies assessing psychedelic-assisted therapy to treat nicotine addiction is showing efficacy rates two to three times higher than the current gold standard of treatment,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly. “Our team is eager to start collecting the data needed to bring an approved drug product to market that could potentially save millions of lives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
